Nicole S. Jones, an executive at Cigna Group (NYSE: CI), carried out a planned sale of company stock on March 2, 2026, disposing of 2,307 shares at $288.91 per share for proceeds of $666,515. The disposition was executed pursuant to a Rule 10b5-1 trading plan Jones adopted on May 8, 2025.
The March 2 sale comes after a pair of transactions on February 27, 2026, when Jones sold 1,826 shares and 912 shares at $287.55 per share to meet tax obligations. Those February sales totaled $787,311.
On the same February 27 date, Jones also received equity awards and option grants from Cigna. She acquired 4,133 shares tied to the settlement of strategic performance shares, and received 5,234 restricted shares that will vest in three equal annual installments beginning March 1, 2027. Both of those grants were reported with a value of $0. Additionally, Jones was granted 8,066 employee stock options that become exercisable beginning March 1, 2027, at an exercise price of $287.5475 per share.
Following these movements in late February and early March, Jones' reported direct holdings in Cigna Group common stock stand at 32,647 shares, with an indirect holding of 1,434.7897 shares through participation in a 401(k) plan.
Market context disclosed with the filings notes that Cigna was trading at $283.93 at the time of reporting. InvestingPro analysis cited in the filings places the stock among companies on its Most Undervalued list. The company is described as carrying a market capitalization of $76.65 billion and trading at a price-to-earnings ratio of 12.76.
Cigna's reported operating performance for the fourth quarter of 2025 was highlighted alongside the insider activity. The company posted earnings per share of $8.08, above the market expectation of $7.88, and reported revenue of $72.47 billion versus a consensus forecast of $70.31 billion. The filings attribute these results in part to robust growth in Cigna's specialty pharmacy unit and its innovative healthcare offerings.
Alongside the financial results, the company disclosed analyst action and leadership changes. TD Cowen raised its price target for Cigna to $338 while maintaining a Buy rating, citing the resolution of prior concerns related to stop loss and pharmacy benefit manager reform. In governance news, Cigna announced that Brian Evanko will succeed David M. Cordani as chief executive officer effective July 1, 2026. Cordani will transition to the role of executive chair of the company's board of directors, and Evanko, currently serving as president and chief operating officer, will join the board.
These filings and announcements together document a sequence of rule-plan sales, tax-related disposals, equity settlements and option grants for an insider, set against a backdrop of stronger-than-expected quarterly results, an upward analyst price-target adjustment and an announced CEO succession.
Summary
Nicole S. Jones sold 2,307 shares on March 2, 2026 under a Rule 10b5-1 plan for $666,515 and previously sold additional shares on February 27 to cover taxes. On February 27 she also received performance-settlement shares, restricted stock that vests beginning March 1, 2027, and options exercisable beginning March 1, 2027. After the transactions she directly owns 32,647 shares and indirectly 1,434.7897 shares via a 401(k). Cigna reported stronger-than-expected fourth-quarter 2025 results and disclosed a planned CEO transition effective July 1, 2026.
Key points
- Insider activity: Jones executed a Rule 10b5-1 sale of 2,307 shares on March 2, 2026 for $666,515 and completed tax-related sales on February 27 totaling $787,311.
- Equity and options: On February 27 Jones acquired 4,133 settlement shares, 5,234 restricted shares vesting in three equal annual installments starting March 1, 2027 (both valued at $0), and 8,066 employee stock options exercisable March 1, 2027 at $287.5475.
- Company performance and governance: Cigna beat Q4 2025 EPS and revenue estimates and announced Brian Evanko will succeed David M. Cordani as CEO on July 1, 2026; TD Cowen raised its price target to $338 while keeping a Buy rating.
Risks and uncertainties
- Insider sales may be interpreted variously by market participants - this can affect investor perception in the healthcare and financial markets, particularly for stocks with notable insider transactions.
- Future vesting schedules and option exercisability dates (beginning March 1, 2027) introduce timing uncertainty around when additional shares or exercises may enter the market, which can influence liquidity considerations in equity markets.
- Analyst sentiment and price targets, such as TD Cowen's raise to $338, reflect updated assessments but are subject to change based on evolving operational or regulatory developments affecting the healthcare and pharmacy benefit manager sectors.